QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (62) Citing Articles via Google Scholar Google Scholar Articles by Tella, S. R. Articles by Cadet, J. L. Search for Related Content PubMed PubMed Citation Articles by Tella, S. R. Articles by Cadet, J. L.

 Previous Article  |  Next Article 

Volume 16, Number 23, Issue of December 1, 1996 pp. 7416-7427
Copyright ©1996 Society for Neuroscience

Differential Reinforcing Effects of Cocaine and GBR-12909: Biochemical Evidence for Divergent Neuroadaptive Changes in the Mesolimbic Dopaminergic System

Received July 18, 1996; revised Sept. 9, 1996; accepted Sept. 12, 1996.

Srihari R. Tella^{1, 2}, Bruce Ladenheim³, Anne M. Andrews⁴, Steven R. Goldberg^{1, 2}, and Jean Lud Cadet³

¹ Department of Pharmacology, Georgetown University School of Medicine, Washington, DC 20007, ² Behavioral Pharmacology and Genetics Section and ³ Molecular Neuropsychiatry Section, National Institutes of Health/National Institute on Drug Abuse, Division of Intramural Research, Baltimore, Maryland 21224, and ⁴ Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland 20892

The dopamine (DA) transporter is thought to be the primary mediator of reinforcing effects of cocaine. In the present study, an intravenous drug self-administration procedure, in vitro autoradiography, and HPLC methods were used to investigate possible differences in reinforcing and neuroadaptive responses to cocaine versus GBR-12909, a selective inhibitor of the DA transporter with a postulated therapeutic use in cocaine abuse. Drug-naive rats readily acquired and subsequently maintained cocaine self-administration behavior during 2 hr daily sessions over a prolonged period. In contrast, although GBR-12909 was initially self-administered, both cocaine-naive and cocaine-trained rats failed to maintain self-administration behavior for GBR-12909 over prolonged periods of time. After self-administration responding decreased with GBR-12909, rats showed a delay of 6.6 ± 1.3 sessions in reacquiring consistent cocaine self-administration. Moreover, when GBR-12909 was again substituted for cocaine, they failed to self-administer GBR-12909, even during the initial days of testing. In contrast, after extinction of self-administration responding by water substitution, rats readily self-administered both cocaine and GBR-12909. Cocaine self-administration upregulated DA transporters, whereas water-substituted cocaine withdrawal upregulated both DA transporters and D1 receptors. Unlike cocaine, GBR-12909 self-administration by itself altered neither DA transporters nor D1 or D2 receptors. Nevertheless, substitution of GBR-12909 for cocaine reversed the cocaine-induced upregulation of DA transporters and reduced DA and dihydroxyphenylacetic acid levels in the mesolimbic system. These data suggest that cocaine and GBR-12909 differentially affect dopaminergic systems and also cause different reinforcing and neuroadaptive effects. GBR-12909-like compounds may be useful pharmacotherapeutic agents for cocaine addiction. Upregulation of DA transporters and D1 receptors might play important roles in the neuroadaptive cascade that leads to cocaine addiction and withdrawal.

Key words: cocaine; GBR-12909; self-administration; reinforcing effects; neuroadaptation; dopamine receptors; dopamine transporters; dopamine; drug addiction; drug withdrawal

This article has been cited by other articles:

				V. Murthy, T. J. Martin, S. Kim, H. M. L. Davies, and S. R. Childers In Vivo Characterization of a Novel Phenylisothiocyanate Tropane Analog at Monoamine Transporters in Rat Brain J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 587 - 595. [Abstract] [Full Text] [PDF]

				B. Roelands, M. Goekint, E. Heyman, M. F. Piacentini, P. Watson, H. Hasegawa, L. Buyse, F. Pauwels, G. De Schutter, and R. Meeusen Acute norepinephrine reuptake inhibition decreases performance in normal and high ambient temperature J Appl Physiol, July 1, 2008; 105(1): 206 - 212. [Abstract] [Full Text] [PDF]

				H. Hasegawa, M. F. Piacentini, S. Sarre, Y. Michotte, T. Ishiwata, and R. Meeusen Influence of brain catecholamines on the development of fatigue in exercising rats in the heat J. Physiol., January 1, 2008; 586(1): 141 - 149. [Abstract] [Full Text] [PDF]

				N. T. Bello, K. L. Sweigart, J. M. Lakoski, R. Norgren, and A. Hajnal Restricted feeding with scheduled sucrose access results in an upregulation of the rat dopamine transporter Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2003; 284(5): R1260 - R1268. [Abstract] [Full Text] [PDF]

				A. P. Kozikowski, K. M. Johnson, O. Deschaux, B. C. Bandyopadhyay, G. L. Araldi, G. Carmona, P. Munzar, M. P. Smith, R. L. Balster, P. M. Beardsley, et al. Mixed Cocaine Agonist/Antagonist Properties of (+)-Methyl 4beta -(4-Chlorophenyl)-1-methylpiperidine-3alpha -carboxylate, a Piperidine-Based Analog of Cocaine J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 143 - 150. [Abstract] [Full Text]

				W. L. Woolverton, R. Ranaldi, Z. Wang, G. A. Ordway, I. A. Paul, P. Petukhov, and A. Kozikowski Reinforcing Strength of a Novel Dopamine Transporter Ligand: Pharmacodynamic and Pharmacokinetic Mechanisms J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 211 - 217. [Abstract] [Full Text] [PDF]

				S. L. Sell and C. P. France Cocaine and Amphetamine Attenuate the Discriminative Stimulus Effects of Naltrexone in Opioid-Dependent Rhesus Monkeys J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1103 - 1110. [Abstract] [Full Text] [PDF]

				M. H. Baumann, M. A. Ayestas, L. G. Sharpe, D. B. Lewis, K. C. Rice, and R. B. Rothman Persistent Antagonism of Methamphetamine-Induced Dopamine Release in Rats Pretreated with GBR12909 Decanoate J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1190 - 1197. [Abstract] [Full Text] [PDF]

				C. J. Loland, L. Norregaard, T. Litman, and U. Gether Generation of an activating Zn2+ switch in the dopamine transporter: Mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle PNAS, January 24, 2002; (2002) 32386299. [Abstract] [Full Text] [PDF]

				S. A. Cherstniakova, D. Bi, D. R. Fuller, J. Z. Mojsiak, J. M. Collins, and L. R. Cantilena Metabolism of Vanoxerine, 1-[2-[bis(4-Fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) Piperazine, by Human Cytochrome P450 Enzymes Drug Metab. Dispos., September 1, 2001; 29(9): 1216 - 1220. [Abstract] [Full Text] [PDF]

				S. R. Letchworth, M. A. Nader, H. R. Smith, D. P. Friedman, and L. J. Porrino Progression of Changes in Dopamine Transporter Binding Site Density as a Result of Cocaine Self-Administration in Rhesus Monkeys J. Neurosci., April 15, 2001; 21(8): 2799 - 2807. [Abstract] [Full Text] [PDF]

				A. J. Eshleman, K. Wolfrum, D. C. Mash, K. Christensen, and A. Janowsky Drug Interactions with the Dopamine Transporter in Cryopreserved Human Caudate J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 442 - 449. [Abstract] [Full Text]

				Y. Fang and O. K. Ronnekleiv Cocaine Upregulates the Dopamine Transporter in Fetal Rhesus Monkey Brain J. Neurosci., October 15, 1999; 19(20): 8966 - 8978. [Abstract] [Full Text] [PDF]

				A. J. Eshleman, M. Carmolli, M. Cumbay, C. R. Martens, K. A. Neve, and A. Janowsky Characteristics of Drug Interactions with Recombinant Biogenic Amine Transporters Expressed in the Same Cell Type J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 877 - 885. [Abstract] [Full Text]

				B. K. Tolliver, A. H. Newman, J. L. Katz, L. B. Ho, L. M. Fox, K. Hsu Jr., and S. P. Berger Behavioral and Neurochemical Effects of the Dopamine Transporter Ligand 4-Chlorobenztropine Alone and in Combination with Cocaine In Vivo J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 110 - 122. [Abstract] [Full Text]

				R. A. Vaughan, G. E. Agoston, J. R. Lever, and A. H. Newman Differential Binding of Tropane-Based Photoaffinity Ligands on the Dopamine Transporter J. Neurosci., January 15, 1999; 19(2): 630 - 636. [Abstract] [Full Text] [PDF]

				G. Le Pen, D. Duterte-Boucher, and J. Costentin Sensitization to the Rewarding Effects of the Specific Dopamine Uptake Inhibitor GBR12783 J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 688 - 696. [Abstract] [Full Text]

				K. I. Bolla, J.-L. Cadet, and E. D. London The Neuropsychiatry of Chronic Cocaine Abuse J Neuropsychiatry Clin Neurosci, August 1, 1998; 10(3): 280 - 289. [Abstract] [Full Text]

				S. R. Tella, B. Ladenheim, and J. L. Cadet Differential Regulation of Dopamine Transporter after Chronic Self-administration of Bupropion and Nomifensine J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 508 - 513. [Abstract] [Full Text]

				C. J. Loland, L. Norregaard, T. Litman, and U. Gether Generation of an activating Zn2+ switch in the dopamine transporter: Mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle PNAS, February 5, 2002; 99(3): 1683 - 1688. [Abstract] [Full Text] [PDF]

				E. Carboni, A. Silvagni, M. T. P. Rolando, and G. Di Chiara Stimulation of In Vivo Dopamine Transmission in the Bed Nucleus of Stria Terminalis by Reinforcing Drugs J. Neurosci., October 15, 2000; 20(20): RC102 - RC102. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help